Piper Jaffray analyst Christopher Raymond says a survey done by his firm's partners at Spherix Global Insights of 102 dermatologists "hints at" plateauing atopic dermatitis use trends for Regeneron Pharmaceuticals' Dupixent. The average number of patients per Dupixent prescriber was up just 0.2 quarter-over-quarter to 15.7, despite prior survey feedback showing projected patients per prescriber up by 8.6 patients, Ramymond tells investors in a research note. However, the analyst points out that this is just "one data point in yet another otherwise very positive survey that continues to indicate significantly increasing use projections." Further, script trends would seem to indicate that strong uptake continues unabated, says Raymond. He views the survey feedback as something worth monitoring, but feels it is not thesis changing, especially with asthma uptake happening now and adolescent atopic dermatitis labeling a "significant" tailwind in the first half of 2019. He keeps an Overweight rating on Regeneron with a $450 price target.